Will the reclassification of marijuana from a Schedule I to a Schedule III drug disrupt the cannabis marketplace?
What consequences must industry stakeholders consider if the Drug Enforcement Administration's proposal becomes a reality?
On this episode, special guests Anthony Minniti, a New Jersey-licensed pharmacist, and Stacey Udell, an accountant with expertise in representing cannabis operators across the United States, join Epstein Becker Green attorney Lisa Gora to See more +
Will the reclassification of marijuana from a Schedule I to a Schedule III drug disrupt the cannabis marketplace?
What consequences must industry stakeholders consider if the Drug Enforcement Administration's proposal becomes a reality?
On this episode, special guests Anthony Minniti, a New Jersey-licensed pharmacist, and Stacey Udell, an accountant with expertise in representing cannabis operators across the United States, join Epstein Becker Green attorney Lisa Gora to discuss the regulatory domino effect and tax implications related to this major potential change to the cannabis industry.
Visit our site for more: https://www.ebglaw.com/dhc77
The Diagnosing Health Care podcast series examines the business opportunities and solutions that exist despite the high-stakes legal, policy, and regulatory issues that the health care industry faces. Subscribe on your favorite podcast platform. See less -
